Cross-protective immunity against influenza virus infections induced by intranasal vaccination together with a TLR3-mucosal adjuvant

Human Vaccines

Volumn 7, Issue SUPPL., 2011, Pages 174-182

  Ainai, Akira ^a   Tashiro, Masato ^a   Hasegawa, Hideki ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Cross protection; Influenza virus; Intranasal vaccination; Mucosal adjuvant; Secretory IgA antibody

Indexed keywords

DOUBLE STRANDED RNA; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; RINTATOLIMOD; TOLL LIKE RECEPTOR 3; ZYMOSAN;

CHRONIC FATIGUE SYNDROME; CLINICAL EFFECTIVENESS; CROSS PROTECTION; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOGENICITY; IMMUNOGLOBULIN PRODUCTION; IMMUNOMODULATION; IMMUNOREACTIVITY; INFECTION PREVENTION; INFLUENZA; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A; INNATE IMMUNITY; MUCOSAL IMMUNITY; NONHUMAN; PANDEMIC INFLUENZA; RESPIRATORY EPITHELIUM; REVIEW; TREATMENT DURATION; VACCINE PRODUCTION; VIRUS LOAD; VIRUS STRAIN;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; CROSS PROTECTION; DISEASE MODELS, ANIMAL; IMMUNITY, MUCOSAL; INFLUENZA VACCINES; MICE; ORTHOMYXOVIRIDAE INFECTIONS; RODENT DISEASES; SURVIVAL ANALYSIS; VACCINATION; VIRAL LOAD;

EID: 84855721890     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.0.14584     Document Type: Review

References (102)

1. Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360:2605-15.
2. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009; 325:197-201.
3. Smith GJ, Vijaykrishna D, Bahl J, Lycett SJ, Worobey M, Pybus OG, et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 2009; 459:1122-5.
4. Centers for Disease Control and Prevention, Swine influenza A(H1N1) infection in two children-Southern California, March-April 2009. Morb Mortal Wkly Rep 2009; 58:400-2.
5. Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 2009; 459:931-9.
6. Nakajima N, Hata S, Sato Y, Tobiume M, Katano H, Kaneko K, et al. The first autopsy case of pandemic influenza (A/H1N1pdm) virus infection in Japan: detection of a high copy number of the virus in type II alveolar epithelial cells by pathological and virological examination. Jpn J Infect Dis 2010; 63:67-71.
7. Kuroda M, Katano H, Nakajima N, Tobiume M, Ainai A, Sekizuka T, et al. Characterization of quasispecies of pandemic 2009 influenza A virus (A/H1N1/2009) by de novo sequencing using a next-generation DNA sequencer. PLoS One 2010; 5:10256.
8. Shieh WJ, Blau DM, Denison AM, Deleon-Carnes M, Adem P, Bhatnagar J, et al. 2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States. Am J Pathol 2010; 177:166-75.
9. thed. Philadelphia: Lippincott Williams & Wilkins 1996; 1397-445.
10. Salomon R, Webster RG. The influenza virus enigma. Cell 2009; 136:402-10.
11. Hien TT, de Jong M, Farrar J. Avian influenza-a challenge to global health care structures. N Engl J Med 2004; 351:2363-5. (Pubitemid 40485985)
12. Subbarao K, Joseph T. Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev Immunol 2007; 7:267-78. (Pubitemid 46480953)
13. Subbarao K, Klimov A, Katz J, Regnery H, Lim W, Hall H, et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 1998; 279:393-6. (Pubitemid 28063376)
14. Claas EC, Osterhaus AD, van Beek R, De Jong JC, Rimmelzwaan GF, Senne DA, et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998; 351:472-7. (Pubitemid 28070093)
15. Peiris JS, Yu WC, Leung CW, Cheung CY, Ng WF, Nicholls JM, et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 2004; 363:617-9. (Pubitemid 38264181)
16. Tran TH, Nguyen TL, Nguyen TD, Luong TS, Pham PM, Nguyen VC, et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 2004; 350:1179-88.
17. Grose C, Chokephaibulkit K. Avian influenza virus infection of children in Vietnam and Thailand. Pediatr Infect Dis J 2004; 23:793-4. (Pubitemid 39063305)
18. Morris SK. H5N1 avian influenza, Kampot Province, Cambodia. Emerg Infect Dis 2006; 12:170-1. (Pubitemid 43143560)
19. Sedyaningsih ER, Isfandari S, Setiawaty V, Rifati L, Harun S, Purba W, et al. Epidemiology of cases of H5N1 virus infection in Indonesia, July 2005-June 2006. J Infect Dis 2007; 196:522-7. (Pubitemid 47206097)
20. Ungchusak K, Auewarakul P, Dowell SF, Kitphati R, Auwanit W, Puthavathana P, et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med 2005; 352:333-40.
21. Wang H, Feng Z, Shu Y, Yu H, Zhou L, Zu R, et al. Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China. Lancet 2008; 371:1427-34.
22. Renger KB, Small PA Jr. Passive immunization: systemic and mucosal. In: Ogra PL, Mestecky J, Lamm ME, Strober W, McGee JR, Bienenstock J, Ed(s). Handbook of Mucosal Immunology. San Diego: Academic Press 1994; 333-43.
23. Chen Z, Sahashi Y, Matsuo K, Asanuma H, Takahashi H, Iwasaki T, et al. Comparison of the ability of viral protein-expressing plasmid DNAs to protect against influenza. Vaccine 1998; 16:1544-9. (Pubitemid 28366091)
24. Chen Z, Kadowaki S, Hagiwara Y, Yoshikawa T, Sata T, Kurata T, et al. Protection against influenza B virus infection by immunization with DNA vaccines. Vaccine 2001; 19:1446-55. (Pubitemid 32332729)
25. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7- mediated recognition of single-stranded RNA. Science 2004; 303:1529-31. (Pubitemid 38314425)
26. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW, et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci USA 2004; 101:5598-603. (Pubitemid 38481202)
27. Honda K, Yanai H, Mizutani T, Negishi H, Shimada N, Suzuki N, et al. Role of a transductional-transcriptional processor complex involving MyD88 and IRF-7 in Toll-like receptor signaling. Proc Natl Acad Sci USA 2004; 101:15416-21. (Pubitemid 39441556)
28. Kawai T, Sato S, Ishii KJ, Coban C, Hemmi H, Yamamoto M, et al. Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol 2004; 5:1061-8. (Pubitemid 41057726)
29. Guillot L, Le Goffic R, Bloch S, Escriou N, Akira S, Chignard M, et al. Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. J Biol Chem 2005; 280:5571-80. (Pubitemid 40280035)
30. Honda K, Sakaguchi S, Nakajima C, Watanabe A, Yanai H, Matsumoto M, et al. Selective contribution of IFNalpha/beta signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection. Proc Natl Acad Sci USA 2003; 100:10872-7. (Pubitemid 37140120)
31. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NFkappaB by Toll-like receptor 3. Nature 2001; 413:732-8. (Pubitemid 33009951)
32. Doyle S, Vaidya S, O'Connell R, Dadgostar H, Dempsey P, Wu T, et al. IRF3 mediates a TLR3/ TLR4-specific antiviral gene program. Immunity 2002; 17:251-63. (Pubitemid 35279547)
33. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003; 301:640-3. (Pubitemid 36927946)
34. Matsumoto M, Funami K, Tanabe M, Oshiumi H, Shingai M, Seto Y, et al. Subcellular localization of Toll-like receptor 3 in human dendritic cells. J Immunol 2003; 171:3154-62. (Pubitemid 37093540)
35. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004; 5:730-7. (Pubitemid 39023305)
36. Kato H, Sato S, Yoneyama M, Yamamoto M, Uematsu S, Matsui K, et al. Cell type-specific involvement of RIG-I in antiviral response. Immunity 2005; 23:19-28. (Pubitemid 41019654)
37. Yoneyama M, Kikuchi M, Matsumoto K, Imaizumi T, Miyagishi M, Taira K, et al. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5 and LGP2 in antiviral innate immunity. J Immunol 2005; 175:2851-8. (Pubitemid 41170502)
38. Kawai T, Takahashi K, Sato S, Coban C, Kumar H, Kato H, et al. IPS-1, an adaptor triggering RIG-Iand Mda5-mediated type I interferon induction. Nat Immunol 2005; 6:981-8. (Pubitemid 41486182)
39. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006; 441:101-5.
40. Pichlmair A, Schulz O, Tan CP, Naslund TI, Liljestrom P, Weber F, et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5′-phosphates. Science 2006; 314:997-1001. (Pubitemid 44749946)
41. Hornung V, Ellegast J, Kim S, Brzozka K, Jung A, Kato H, et al. 5'-Triphosphate RNA is the ligand for RIG-I. Science 2006; 314:994-7.
42. Kato H, Takeuchi O, Mikamo-Satoh E, Hirai R, Kawai T, Matsushita K, et al. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J Exp Med 2008; 205:1601-10. (Pubitemid 351962024)
43. Ichinohe T, Lee HK, Ogura Y, Flavell R, Iwasaki A. Inflammasome recognition of influenza virus is essential for adaptive immune responses. J Exp Med 2009; 206:79-87.
44. Ichinohe T, Pang IK, Iwasaki A. Influenza virus activates inflammasomes via its intracellular M2 ion channel. Nat Immunol 2010; 11:404-10.
45. Allen IC, Scull MA, Moore CB, Holl EK, McElvania- TeKippe E, Taxman DJ, et al. The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity 2009; 30:556-65.
46. Thomas PG, Dash P, Aldridge JR Jr, Ellebedy AH, Reynolds C, Funk AJ, et al. The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity 2009; 30:566-75.
47. Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 2008; 9:847-56.
48. Li H, Willingham SB, Ting JP, Re F. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol 2008; 181:17-21.
49. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2:675-80. (Pubitemid 32747155)
50. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5:987-95. (Pubitemid 41057715)
51. Albert ML, Jegathesan M, Darnell RB. Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells. Nat Immunol 2001; 2:1010-7. (Pubitemid 33069495)
52. Ada GL, Jones PD. The immune response to influenza infection. Curr Top Microbiol Immunol 1986; 128:1-54.
53. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+T-helper and a T-killer cell. Nature 1998; 393:474-8. (Pubitemid 128728267)
54. Riberdy JM, Christensen JP, Branum K, Doherty PC. Diminished primary and secondary influenza virus-specific CD8(+) T-cell responses in CD4-depleted Ig(-/-) mice. J Virol 2000; 74:9762-5.
55. Nonacs R, Humborg C, Tam JP, Steinman RM. Mechanisms of mouse spleen dendritic cell function in the generation of influenza-specific, cytolytic T lymphocytes. J Exp Med 1992; 176:519-29.
56. + T cells clear influenza virus by perforin or Fas-dependent processes. J Immunol 1997; 159:5197-200.
57. Johnson BJ, Costelloe EO, Fitzpatrick DR, Haanen JB, Schumacher TN, Brown LE, et al. Single-cell perforin and granzyme expression reveals the anatomical localization of effector CD8+ T cells in influenza virus-infected mice. Proc Natl Acad Sci USA 2003; 100:2657-62. (Pubitemid 36297554)
58. Brandtzag P, Krajci P, Lamm ME, Kaetzl CS. Epitherial and hepatobiliary transort of polymeric immunogloburins. In: Ogra PL, Mestecky J, Lamm ME, Strober W, McGee JR, Bienenstock J, Ed(s). Handbook of Mucosal Immunology. San Diego: Academic Press 1994; 113-26.
59. Strugnell RA, Wijburg OL. The role of secretory antibodies in infection immunity. Nat Rev Microbiol 2010; 8:656-67.
60. Asahi Y, Yoshikawa T, Watanabe I, Iwasaki T, Hasegawa H, Sato Y, et al. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines. J Immunol 2002; 168:2930-8. (Pubitemid 34211673)
61. Asahi-Ozaki Y, Yoshikawa T, Iwakura Y, Suzuki Y, Tamura S, Kurata T, et al. Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus. J Med Virol 2004; 74:328-35. (Pubitemid 39150401)
62. Mazanec MB, Coudret CL, Fletcher DR. Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies. J Virol 1995; 69:1339-43.
63. Couch RB, Kasel JA. Immunity to influenza in man. Annu Rev Microbiol 1983; 37:529-49.
64. Murphy BR. Mucosal Immunity to Viruses. In: Ogra PL, Mestecky J, Lamm ME, Strober W, McGee JR, Bienenstock J, Ed(s). Handbook of Mucosal Immunology. San Diego: Academic Press 1994; 333-43.
65. Murphy BR, Clements ML. The systemic and mucosal immune response of humans to influenza A virus. Curr Top Microbiol Immunol 1989; 146:107-16.
66. + T cell-dependent immunoglobulin A response to influenza infection in the absence of key cognate T-B interactions. J Exp Med 2003; 198:1011-21.
67. Tamura S, Tanimoto T, Kurata T. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn J Infect Dis 2005; 58:195-207. (Pubitemid 41460922)
68. Centers for Disease Control and Prevention, Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP) 2009. Morb Mortal Wkly Rep 2009; 58:1-52.
69. Koyama S, Aoshi T, Tanimoto T, Kumagai Y, Kobiyama K, Tougan T, et al. Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes. Sci Transl Med 2010; 2:25.
70. Keitel WA, Piedra PA. Live cold-adapted, reassortant inflenza vaccines (USA). In: Nicholson KG, Webster RG, Hay RJ, Ed(s). Textbook of influenza. London: Blackwell Scientific Publications 1998; 373-90.
71. Renegar KB, Small PA Jr, Boykins LG, Wright PF. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 2004; 173:1978-86. (Pubitemid 38971634)
72. Ito R, Ozaki YA, Yoshikawa T, Hasegawa H, Sato Y, Suzuki Y, et al. Roles of anti-hemagglutinin IgA and IgG antibodies in different sites of the respiratory tract of vaccinated mice in preventing lethal influenza pneumonia. Vaccine 2003; 21:2362-71. (Pubitemid 36561328)
73. Ramphal R, Cogliano RC, Shands JW Jr, Small PA Jr. Serum antibody prevents lethal murine influenza pneumonitis but not tracheitis. Infect Immun 1979; 25:992-7. (Pubitemid 9251906)
74. Palladino G, Mozdzanowska K, Washko G, Gerhard W. Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. J Virol 1995; 69:2075-81.
75. Tamura S, Samegai Y, Kurata H, Nagamine T, Aizawa C, Kurata T. Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit. Vaccine 1988; 6:409-13.
76. Tamura S, Yamanaka A, Shimohara M, Tomita T, Komase K, Tsuda Y, et al. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine. Vaccine 1994; 12:419-26. (Pubitemid 24107578)
77. Tamura SI, Asanuma H, Ito Y, Hirabayashi Y, Suzuki Y, Nagamine T, et al. Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine. Eur J Immunol 1992; 22:477-81.
78. Tamura S, Ito Y, Asanuma H, Hirabayashi Y, Suzuki Y, Nagamine T, et al. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. J Immunol 1992; 149:981-8.
79. Durrer P, Gluck U, Spyr C, Lang AB, Zurbriggen R, Herzog C, et al. Mucosal antibody response induced with a nasal virosome-based influenza vaccine. Vaccine 2003; 21:4328-34. (Pubitemid 37130275)
80. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004; 350:896-903. (Pubitemid 38252537)
81. Ichinohe T, Watanabe I, Ito S, Fujii H, Moriyama M, Tamura S, et al. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J Virol 2005; 79:2910-9. (Pubitemid 40270569)
82. Ichinohe T, Tamura S, Kawaguchi A, Ninomiya A, Imai M, Itamura S, et al. Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. J Infect Dis 2007; 196:1313-20. (Pubitemid 351412003)
83. Ichinohe T, Kawaguchi A, Tamura S, Takahashi H, Sawa H, Ninomiya A, et al. Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge. Microbes Infect 2007; 9:1333-40. (Pubitemid 47539208)
84. Hasegawa H, Ichinohe T, Strong P, Watanabe I, Ito S, Tamura S, et al. Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant. J Med Virol 2005; 75:130-6. (Pubitemid 39578800)
85. Ichinohe T, Watanabe I, Tao E, Ito S, Kawaguchi A, Tamura S, et al. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant. J Med Virol 2006; 78:954-63. (Pubitemid 43856705)
86. Kamijuku H, Nagata Y, Jiang X, Ichinohe T, Tashiro T, Mori K, et al. Mechanism of NKT cell activation by intranasal coadministration of alpha-galactosyl-ceramide, which can induce cross-protection against influenza viruses. Mucosal Immunol 2008; 1:208-18. (Pubitemid 351541306)
87. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001; 14:461-70. (Pubitemid 32441598)
88. Robinson RA, DeVita VT, Levy HB, Baron S, Hubbard SP, Levine AS. A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors. J Natl Cancer Inst 1976; 57:599-602.
89. Strayer DR, Carter WA, Brodsky I, Cheney P, Peterson D, Salvato P, et al. A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome. Clin Infect Dis 1994; 18:88-95.
90. Suhadolnik RJ, Reichenbach NL, Hitzges P, Adelson ME, Peterson DL, Cheney P, et al. Changes in the 2-5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly(I)-poly(C12U) in chronic fatigue syndrome. In Vivo 1994; 8:599-604. (Pubitemid 24341140)
91. Thompson KA, Strayer DR, Salvato PD, Thompson CE, Klimas N, Molavi A, et al. Results of a doubleblind placebo-controlled study of the double-stranded RNA drug polyI:polyC12U in the treatment of HIV infection. Eur J Clin Microbiol Infect Dis 1996; 15:580-7.
92. Ichinohe T, Ainai A, Ami Y, Nagata N, Iwata N, Kawaguchi A, et al. Intranasal administration of adjuvant- combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus. J Med Virol 2010; 82:1754-61.
93. Ainai A, Ichinohe T, Tamura S, Kurata T, Sata T, Tashiro M, et al. Zymosan enhances the mucosal adjuvant activity of poly(I:C) in a nasal influenza vaccine. J Med Virol 2010; 82:476-84.
94. Di Carlo FJ, Fiore JV. On the composition of zymosan. Science 1958; 127:756-7.
95. Gantner BN, Simmons RM, Canavera SJ, Akira S, Underhill DM. Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J Exp Med 2003; 197:1107-17. (Pubitemid 36570066)
96. Slack EC, Robinson MJ, Hernanz-Falcon P, Brown GD, Williams DL, Schweighoffer E, et al. Sykdependent ERK activation regulates IL-2 and IL-10 production by DC stimulated with zymosan. Eur J Immunol 2007; 37:1600-12. (Pubitemid 46939495)
97. Herre J, Marshall AS, Caron E, Edwards AD, Williams DL, Schweighoffer E, et al. Dectin-1 uses novel mechanisms for yeast phagocytosis in macrophages. Blood 2004; 104:4038-45. (Pubitemid 39620154)
98. Robinson MJ, Sancho D, Slack EC, LeibundGut- Landmann S, Reis e Sousa C. Myeloid C-type lectins in innate immunity. Nat Immunol 2006; 7:1258-65. (Pubitemid 46111243)
99. Brown GD. Dectin-1: a signalling non-TLR pattern-recognition receptor. Nat Rev Immunol 2006; 6:33-43. (Pubitemid 43279751)
100. Rogers NC, Slack EC, Edwards AD, Nolte MA, Schulz O, Schweighoffer E, et al. Syk-dependent cytokine induction by Dectin-1 reveals a novel pattern recognition pathway for C type lectins. Immunity 2005;22:507-17. (Pubitemid 40545115)
101. Gross O, Gewies A, Finger K, Schafer M, Sparwasser T, Peschel C, et al. Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Nature 2006; 442:651-6. (Pubitemid 44215314)
102. Bagchi A, Herrup EA, Warren HS, Trigilio J, Shin HS, Valentine C, et al. MyD88-dependent and MyD88-independent pathways in synergy, priming and tolerance between TLR agonists. J Immunol 2007; 178:1164-71. (Pubitemid 46095190)